1998 Annual Meeting

HTML> 1998 Annual Meeting

Sunday, May 30

7:30 a.m.-5 p.m.

Registration/Course Enrollment Open

8 a.m.-Noon

CME Courses 15-20

8 a.m.-5 p.m.

APA Resource Center Open

9 a.m.-Noon

Industry-Supported Symposia

IS10. Women and Psychosis: From Lab Bench to Clinical Practice Supported by Eli Lilly and Company
A. Effects of Gonadal Steroids on Brain and Behavior David R. Rubinow, M.D.
B. Sex and Brain Abnormalities in Schizophrenia Jill M. Goldstein, Ph.D.
C. Sex and Neuroendocrine Differences Following Treatment With Typical and Atypical Antipsychotics Lee S. Cohen, M.D.
D. Women, Prolactin, and the New Neuroleptics Ruth A. Dickson, M.D.
E. Atypical Antipsychotics in Women With Bipolar and Other Psychiatric Disorders Susan L. McElroy, M.D.

IS11. New Treatments for Anxiety Disorders: Clinical Approaches for Successful Outcomes Supported by SmithKline Beecham Pharmaceuticals
A. Gender Differences in the Epidemiology and Treatment of Anxiety Disorders Teresa A. Pigott, M.D.
B. Current Concepts in the Treatment of Panic Disorder David V. Sheehan, M.D.
C. Update on the Diagnosis and Treatment of Social Phobia Michael R. Liebowitz, M.D.
D. OCD: Diagnosis and Treatment Wayne K. Goodman, M.D.
E. PTSD: Diagnostic and Therapeutic Issues Jonathan R.T. Davidson, M.D.

IS12. Intervention for Refractory Bipolar Disorder Supported by GlaxoWellcome Inc
. A. Management of Treatment-Refractory Bipolar Depression Gary S. Sachs, M.D.
B. Bipolar Disorder: Expert Consensus Survey Results David A. Kahn, M.D.
C. Alternative Treatment for Refractory Mania/Cycling Robert M. Post, M.D.
D. Options for Treatment-Refractory Rapid Cycling Joseph R. Calabrese, M.D.
E. Cognitive Behavioral Strategies for Bipolar Patients Noreen A. Reilly-Harrington, Ph.D.

IS13. Individualizing the Treatment of Psychoses Supported by Zeneca Pharmaceutical
s A. Impact of Phases and Severity of Illness on Treatment Decisions Across the Age Spectrum Robert L. Findling, M.D.
B. Management of Psychotic Aspects of Schizoaffective Disorder Stephen M. Strakowski, M.D.
C. Treatment Issues With the Use of Antipsychotic Medications Sharon G. Dott, M.D.
D. Schizophrenia and Comorbidity Jeffrey A. Lieberman, M.D.
E. After Responding: What Happens Next? Peter J. Weiden, M.D.

IS14. Alzheimer's Disease: Practical Treatment Approaches Supported by Novartis Pharmaceuticals Corporation
A. The Natural History of Alzheimer's Disease and the Evolution of Psychiatric Symptoms George T. Grossberg, M.D.
B. The Alzheimer's Disease Patient and Family: Communication, Evaluation, and Management Issues Steven H. Ferris, Ph.D.
C. The Psychiatrist's Role in Day-to-Day Management Peter V. Rabins, M.D
. D. The APA Practice Guidelines: Implications for the Practitioner Elsa M. Zayas, M.D
.

IS15. Chronic Depression: Optimizing Long-Term Treatment Supported by Bristol-Myers Squibb
A. Epidemiology and Clinical Course of Chronic Depression Martin B. Keller, M.D.
B. Enhancing Compliance With Antidepressant Treatment: Identification and Management of Side Effects John M. Zajecka, M.D.
C. Chronic Depression: Managing Emerging Bipolar Symptoms David L. Dunner, M.D.
D. Gender Issues in Chronic Depression: Implications for Treatment Susan G. Kornstein, M.D.
E. Combining Pharmacotherapy With Psychosocial Treatments Gabor I. Keitner, M.D.

IS16. Issues in the Long-Term Management of Depression Supported by Organon Inc.
A. Long-Term Nature of Depression Michael E. Thase, M.D.
B. New Developments in Acute Treatment of Depression Stuart A. Montgomery, M.D.
C. Antidepressant Drug Mechanism of Action: Relationship to Efficacy Dennis S. Charney, M.D.
D. Management Issues in Maintenance Treatment A. John Rush, M.D.
E. Management of Sexual Side Effects of Antidepressant Therapy Robert M.A. Hirschfeld, M.D.

IS17. Juvenile Mood Disorders: From Research to Clinical Practice Supported by Wyeth-Ayerst Laboratories
A. ADHD and Juvenile Mania: An Overlooked Comorbidity? Joseph Biederman, M.D.
B. Mania-Like Symptoms Suggestive of Childhood-Onset Bipolar Disorder in Clinically Referred Children Janet Wozniak, M.D.
C. ADHD With Bipolar Disorder: A Familial Subtype? Stephen V. Faraone, Ph.D.
D. Juvenile Bipolar Disorder and the Risk for Substance Abuse Timothy E. Wilens, M.D.
E. The Naturalistic Course of Pharmacologic Treatment of Children With Manic-Like Symptoms: A Systematic Chart Review Thomas J. Spencer, M.D.

9 a.m.-4 p.m.

CME Courses 21-26

11 a.m.-5 p.m.

Exhibits Open

Publishers' Bookfair Open

12:30 p.m.-1:30 p.m.

Business Meeting and Forum

(Voting Members Only)

1 p.m-5 p.m.

CME Courses 27-33

1:30 p.m.-4:30 p.m.

Industry-Supported Symposia

IS18. The Depressed Woman: Contemporary Treatments Supported by Eli Lilly and Company
A. Treatment of Psychiatric Illness During Pregnancy and the Postpartum Period Lee S. Cohen, M.D.
B. Interpersonal Psychotherapy for Antepartum Depression Margaret G. Spinelli, M.D.
C. The Treatment of Depressed Women and Their Children Myrna M. Weissman, Ph.D.
D. Preventing Recurrence of Depression in Women Ellen Frank, Ph.D.
E. New Treatments for Premenstrual Dysphoric Disorder Kimberly A. Yonkers, M.D.

IS19. New Frontiers in the Management of Social Phobia: Diagnosis, Treatment, and Clinical Course Supported by SmithKline Beecham Pharmaceuticals
A. The Differential Diagnosis of Social Phobia Murray B. Stein, M.D.
B. Gender Differences in the Presentation and Management of Social Phobia Lisa S. Weinstock, M.D.
C. Cognitive-Behavior Therapy for Social Phobia: Theory, Outcome, and Future Directions Michael W. Otto, Ph.D.
D. Social Phobia: Designing a Pharmacologic Treatment Strategy Mark H. Pollack, M.D.
E. Comorbid Social Anxiety and Body Dysmorphic Disorder: Managing the Complicated Patient Eric Hollander, M.D.

IS20. Nicotine: An Enemy or an Ally? Supported by GlaxoWellcome Inc.
A. The Neurobiology of Nicotine Dependence George F. Koob, Ph.D.
B. Depressive Relapse Provoked by Smoking Cessation Alexander H. Glassman, M.D.
C. A Nicotinic Receptor Deficit in Schizophrenia Robert Freedman, M.D.
D. Treating Heavily Dependent and Comorbid Smokers John R. Hughes, M.D.
E. Nicotine Dependence in Alcoholics Richard D. Hurt, M.D.

IS21. New Atypicals: Data Versus Clinical Experience Supported by Zeneca Pharmaceuticals
A. Therapeutic Implications of Etiological Research Robin M. Murray, M.B.
B. Atypical Antipsychotics: How Well Do They Really Work? Rajiv Tandon, M.D.
C. Newer Antipsychotics: Side-Effect Profiles Stephen R. Marder, M.D.
D. Services Research and Use of Atypical Antipsychotics Lisa B. Dixon, M.D.
E. Combining Atypicals With Psychosocial Interventions Ira D. Glick, M.D.

IS22. Optimizing Patient Outcomes With Novel Antipsychotics: Changing Expectations Supported by Novartis Pharmaceuticals Corporation
A. Antipsychotic Drugs: Translating Pharmacology Into Clinical Effects David Pickar, M.D.
B. Early Intervention: Can We Change the Course of Illness? Jeffrey A. Lieberman, M.D.
C. Aggression, Violence, and Suicide in Schizophrenia Peter F. Buckley, M.D.
D. Comorbid Substance Abuse: Do Antipsychotic Drugs Have a Role? Alan I. Green, M.D.
E. Beyond Symptoms: Optimizing Real-World Outcomes Jean-Pierre Lindenmayer, M.D.

IS23. The Anxiety Labyrinth: Finding a Pathway to the Solutions Supported by Bristol-Myers Squibb
A. Course and Psychosocial Impairment in GAD Jane L. Eisen, M.D.
B. GAD: Unloved and Misunderstood and Its Relevance to Psychiatry James G. Barbee IV, M.D.
C. Comorbidity: Bad News and Good News R. Bruce Lydiard, M.D.
D. PTSD: Who Responds to What Treatment? Jonathan R.T. Davidson, M.D.

IS24. Depressive Disorders: Advances in Clinical Management Supported by Organon Inc.
A. Depression Subtyping: Treatment Implications Paula J. Clayton, M.D.
B. Strategies for Overcoming Treatment Resistance J. Craig Nelson, M.D.
C. Assessment and Treatment of Depression by Computer John H. Greist, M.D.
D. Dealing With Dangerous and Disturbing Side Effects Edmund C. Settle Jr., M.D.
E. Drug and Diet Interactions: Avoiding Therapeutic Paralysis James W. Jefferson, M.D.

IS25. Treatment of Depression in Difficult Situations Supported by Wyeth-Ayerst Laboratories
A. Depression Adversely Affects Mental and Physical Health Dwight L. Evans, M.D.
B. Treatment of Severe Unipolar and Bipolar Depression Ned H. Kalin, M.D.
C. Treatment of Depression and Comorbid Anxiety Dennis S. Charney, M.D.
D. Recognizing and Treating Body Dysmorphic Disorder in Depressed Patients Katharine A. Phillips, M.D.
E. The Study of Affects With Neuroimaging Raquel E. Gur, M.D.

2:30 p.m.-4 p.m.

Lecture

L1. Two Hats Revisited: Contexts, Complications, and Compromises Between Clinical and Forensic Roles Larry H. Strasburger, M.D., Thomas G. Gutheil, M.D., and Archie Brodsky, B.A., AAPL/APA's Manfred S. Guttmacher Award Lecture

5 p.m.-6:30 p.m.

Opening Session and Presidential Address (paper no. 1)

7 p.m.-10 p.m.

Industry-Supported Symposia

IS26. Expanding the Spectrum of Psychoses: The Interface of Affect Supported by Eli Lilly and Company
A. A Biological Basis for Overlap of Mood in Psychotic Disorders Paul E. Keck Jr., M.D.
B. The Psychopharmacologic Treatment of Schizoaffective Disorder Susan L. McElroy, M.D.
C. Psychotic Major Depression Alan F. Schatzberg, M.D.
D. Experience Using Olanzapine in the Treatment of Acute Bipolar Mania Mauricio Tohen, M.D.
E. Affective Disorders, Tardive Dyskinesia, and Atypical Antipsychotics William M. Glazer, M.D.

IS27. Sexual Dysfunction and the Patient With Depression Supported by GlaxoWellcome Inc.
A. Managing Sexual Side Effects of Antidepressants Troy L. Thompson II, M.D.
B. The Sexual Side Effects of Commonly Prescribed Drugs Theresa L. Crenshaw, M.D.
C. Sexuality and Depression Domeena C. Renshaw, M.D.

IS28. Treatment Strategies for Successful Outcomes in Patients With Panic Disorder Supported by Pfizer U.S. Pharmaceuticals
A. As a Single Measure, Reduction of Panic Attacks Is Insufficient for Assessing Treatment Efficacy in Panic Disorder David A. Spiegel, M.D.
B. Clinical Treatment Strategies for Successful Outcomes in Panic Donald F. Klein, M.D.
C. Pharmacotherapy of Panic Disorder Jack M. Gorman, M.D.
D. Cognitive-Behavioral Therapy of Panic Disorder M. Katherine Shear, M.D.

IS29. Clinical Aspects of Violence Supported by Novartis Pharmaceuticals Corporation
A. Clinical Prediction of Violence Phillip J. Resnick, M.D.
B. Assessment of Violent Threats Park E. Dietz, M.D.
C. Violence: America's Social Illness Robert T. M. Phillips, M.D.
D. Assaults and Threats Against Clinicians John R. Lion, M.D.
E. Pharmacologic Approaches to Violence RenŽe L. Binder, M.D.

IS30. Pharmacotherapy of Bipolar Disorder: Newest Advances Supported by Abbott Laboratories
A. Rapid Loading Strategies in the Treatment of Acute Mania Paul E. Keck Jr., M.D.
B. Bipolar Depression John M. Zajecka, M.D.
C. Maintenance Treatment in Bipolar Disorder Charles L. Bowden, M.D.
D. Substance Abuse Complicating Manic Depression Kathleen T. Brady, M.D.

IS31. Age-Related Memory Loss: Detection and Treatment Supported by Janssen Pharmaceutica and Research Foundation
A. From Age-Related Cognitive Decline to Dementia Steven H. Ferris, Ph.D.
B. Does Depression Predict Cognitive Decline in the Elderly? Davangere P. Devanand, M.D.
C. Methods for Early Detection of Memory Loss Gary W. Small, M.D.
D. From Neurobiology to Novel Treatments Murray A. Raskind, M.D.
E. Current Memory Treatments: Challenges and Prospects Lon S. Schneider, M.D.

IS32. Contemporary Issues in Treatment-Resistant Depression Supported by Wyeth-Ayerst Laboratories
A. Overview of Treatment-Resistant Andrew A. Nierenberg, M.D
B. Algorithms in Treatment-Refractory Depression Jan A. Fawcett, M.D.
C. Estrogen: What Is the Magnitude of the Effect? Barbara B. Sherwin, Ph.D.
D. Combination Treatments in Resistant Depression David Bakish, M.D.
E. Treatment-Resistant Depression: Pushing Out the Edges of the Envelope Jay D. Amsterdam, M.D.

Media Session

Session 1. Toward Healing of Racial and Religious Divisions
1. Blacks and Jews
2. Daughters of the Troubles: Belfast Stories